Pfizer sees strong prospects based on rapid integration of Pharmacia and
expanded product and R&D opportunities

Pfizer Estimates 16 Percent Compounded Annual Growth in Adjusted Diluted
EPS* Between 2002-2004; Pharmacia Acquisition To Add $.06 to Diluted EPS
In 2004

Significant Progress Made Toward Goal Of Filing 20 Medicines By 2006;
Late-Stage Pipeline Includes Major Products In CNS Disorders, Pain,
HIV/AIDS, Cardiovascular Disease And Smoking Cessation; $7.1 Billion R&D
Investment In 2003 Leads Industry

Pfizer Leads Worldwide Pharmaceutical Industry With 33 Major Products In
10 Therapeutic Categories; Pfizer Has Scale And Presence To Reach Large
Untreated Populations

Pfizer Continues Strong Emphasis On Partnerships Providing Patients
Global Access To Innovative Medicines

NEW YORK, June 17 - Pfizer Inc said today it is making rapid progress in
integrating Pharmacia and that the acquisition expands the Company's
deep and broad product line, increases operational flexibility and
improves research and development opportunities.

"Pfizer expects to achieve continued strong performance driven by the
expansion of current products, an enhanced R&D organization and a
strengthened leadership position in all key regions of the world," said
Hank McKinnell, Pfizer's chairman and chief executive officer. "At a
challenging time for our industry, Pfizer is successfully managing scale
and leveraging growth. In 2003, we are rapidly and effectively
integrating Pharmacia. In 2004 and beyond, we see substantial
opportunities for growth as we expand our product portfolio and reach
millions of untreated patients who can benefit from our new medicines.
We will continue to excel in financial performance, corporate
citizenship, and the expansion of access to innovative medicines."

During its first meeting with financial analysts following the April 16
completion of the Pharmacia acquisition, Pfizer leaders highlighted the
following:

· From 2002 to 2004, Pfizer expects compounded annual revenue growth
of 10 percent** and compounded annual adjusted diluted EPS growth of 16
percent from adjusted diluted EPS for legacy Pfizer of $1.59 in 2002. In
2004, Pfizer expects the Pharmacia acquisition will be $.06 accretive to
the adjusted diluted EPS of legacy Pfizer, in line with previous
forecasts.

· The integration of Pharmacia is proceeding well, and the Company
now expects to realize cost synergies of $1 billion in 2003, rising to
$3 billion in 2004 and approaching $4 billion in 2005. Pfizer had
previously estimated cost...